ADBE vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-20.
Adobe Inc. · Technology
$248.16
+45.0% upside to fair value
High Conviction
Grade B
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
JNJ |
| Current Price |
$248.16 |
$230.69 |
| Fair Value Estimate |
$359.82 |
$255.61 |
| Upside to Fair Value |
+45.0%
|
+10.8%
|
| Market Cap |
$101.2B |
$555.9B |
| Forward P/E |
14.1x
|
26.8x
|
| EV / EBITDA |
—
|
18.5x
|
| Price / Sales |
4.1x
|
5.8x
|
| Price / FCF |
9.8x
|
28.2x
|
| Revenue Growth YoY |
+3.3%
|
+9.9%
|
| Gross Margin |
89.1%
|
69.1%
|
| Operating Margin |
36.6%
|
26.9%
|
| Return on Equity |
62.3%
|
26.5%
|
| Dividend Yield |
— |
0% |
| FCF Yield |
10.2%
|
3.54%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
ADBE |
JNJ |
| Zone Low |
$269.87 |
$191.71 |
| Zone High |
$305.85 |
$217.27 |
| In Buy Zone? |
Yes
|
No
|